Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.
暂无分享,去创建一个
A. Jankowska | J. Maciejewski | M. Sekeres | H. Makishima | E. Hsi | H. Szpurka | J. Bodo | N. Bejanyan
[1] A. Kohlmann,et al. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis , 2010, Haematologica.
[2] J. Soulier,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[3] A. Kohlmann,et al. Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). , 2009 .
[4] G. Mufti,et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Birnbaum,et al. Mutations of ASXL1 gene in myeloproliferative neoplasms , 2009, Leukemia.
[6] D. Gilliland,et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.
[7] A. Hagemeijer,et al. Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.
[8] Jungwon Huh,et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.
[9] Daniel Birnbaum,et al. Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.
[10] David R. Liu,et al. Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .
[11] D. Gilliland,et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML , 2009, Leukemia.
[12] D. Gilliland,et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.
[13] J. Maciejewski,et al. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation , 2009, Leukemia.
[14] T. Barbui,et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. , 2008, Blood.
[15] P. Guglielmelli,et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal , 2008, Leukemia.
[16] M. Olschewski,et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis , 2008, Haematologica.
[17] U. Germing,et al. MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 × 109/l , 2008, Annals of Hematology.
[18] M. McDevitt,et al. SNP Array Karyotyping Allows for the Detection of Uniparental Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MPD , 2007, PloS one.
[19] U. Germing,et al. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. , 2007, Blood.
[20] D. Gilliland,et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.
[21] G. Mufti,et al. The JAK2 V617F mutation is rare in RARS but common in RARS-T , 2006, Leukemia.
[22] J. Maciejewski,et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. , 2006, Blood.
[23] B. Quesnel,et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis , 2006, Leukemia.
[24] M. Boissinot,et al. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). , 2006, Blood.
[25] Sandra A. Moore,et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.
[26] B. Woda,et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features , 2006, Leukemia.
[27] S. Mathew,et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) , 2003, Leukemia.
[28] R. Kralovics,et al. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. , 2002, Experimental hematology.
[29] A. Schmitt-Graeff,et al. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. , 2002, Haematologica.
[30] Y. Hayashi,et al. Leukemia-associated Protein with a CXXC Domain , Is Fused to MLL in Acute Myeloid Leukemia with Trilineage Dysplasia Having t ( 10 ; 11 ) ( q 22 ; q 23 ) 1 , 2002 .